/
/
Drogas baseada em citometria de fluxo sistema de triagem para a identificação de pequenas moléculas que promovem a diferenciação celular de células-tronco Glioblastoma
A subscription to JoVE is required to view this content. Sign in or start your free trial.
1Department of Neurological Surgery, Case Comprehensive Cancer Center,Case Western Reserve University School of Medicine, 2Department of Pathology,Johns Hopkins University, School of Medicine, 3Department of Neurological Surgery, University Hospital-Case Medical Center, Case Comprehensive Cancer Center,Case Western Reserve University School of Medicine
Chapters
- 00:05Title
- 01:17Generation of Lentiviral Transcriptional Reporter Cell Lines
- 03:47Subclone Selection, Expansion, and Validation
- 04:47Determination of GFAP:GFP Expression by Flow Cytometry
- 05:58ELDA Self-renewal Assay to Assess Clonogenic Capacity
- 07:01Drug Screen
- 08:27Results: Selection and Drug Screening of Glioblastoma Stem Cell Subclones
- 09:46Conclusion
Um protocolo de triagem eficiente é apresentado para a identificação de pequenas moléculas que promovem a diferenciação de Ralevic em células-tronco glioblastoma (GSCs). O ensaio baseia-se em um repórter de diferenciação de células-tronco no qual a expressão da GFP reforçada (eGFP) é conduzida pelo promotor GFAP humano.
Tags
Flow CytometryDrug ScreeningGlioblastoma Stem CellsCellular DifferentiationLentivirusReporter ConstructHigh-throughput ScreeningSmall MoleculesAstroglial DifferentiationCancer Stem CellsEhlers-Danlos GlioblastomaCell LineageBloodborne PathogensNeural Stem Cell Growth MediumPolybreneDissociation Reagent
